BOC Sciences provides end-to-end formulation development and testing services designed to advance drug discovery programs efficiently. With expertise in solubility enhancement, stability optimization, and targeted delivery systems, we develop customized formulations to meet diverse compound profiles. Our integrated approach ensures high-quality, scalable solutions that align with regulatory standards and accelerate the transition from early-stage research to clinical development.
Accelerate biologic drug development with expert formulation for antibodies, CGTs, proteins, peptides & vaccines—stable, effective, scalable.
Streamline your research with expert assay development, HTS, cellular & biochemical assays, plus protein production services.
Accelerate COVID-19 drug & vaccine development with molecular assays, biologic screening & formulation support targeting SARS-CoV-2 variants.
Ensure stable, clinical-ready drug formulations with our formulation study—stability testing, GMP prep, quality checks & more to speed development.
Gain key insights into stability, solubility & release to avoid setbacks. Optimize your drug's formulation for efficacy & faster development.
Formulation development for all dosage forms—drops, injectables, powders, orals, semi-solids & sprays—ensures stability, bioavailability & compliance.
Boost drug discovery with DMPK/ADME services including metabolism, absorption, distribution, and clearance studies to enhance pharmacokinetics and accelerate development.
Ensure drug safety and compliance with toxicology testing covering toxicity, genotoxicity and safety pharmacology to reduce risks and meet regulations.
Our precise BE/BA studies provide robust bioequivalence and bioavailability testing to validate drug formulations, optimize dosing, and ensure regulatory approval.
Looking for precise, scalable nano drug delivery? We provide expert nanoformulation services with LNP, liposome, nanogel, and protein-based nanoparticle technologies.
BOC Sciences is committed to providing modern, state-of-the-art pharmacy laboratories and facilities including formulation, manufacturing, and drug delivery.
BOC Sciences' bioanalytical laboratories work in a Good Laboratory Practice (GLP) compliant environment, providing method development, transfer, validation and analysis of pre-clinical and clinical biological samples.
BOC Sciences' clinical pharmacokinetics laboratory can support pre-clinical and clinical research programmes through the development and utilisation of bioanalytical methods.
BOC Sciences provides high-quality, customized preclinical research solutions to pharmaceutical companies, research institutions, and scientists worldwide. Leveraging strong scientific expertise and advanced technology platforms, we specialize in formulation development for drug discovery and aesthetic medicine—including nanoparticles, sustained-release systems, transdermal delivery, injectables, and topical creams.
Client-focused and quality-driven, BOC Sciences ensures every project meets strict regulatory standards, supporting efficient and safe progression from concept to clinic. Our flexible, scalable solutions accelerate innovation and enable smooth transition from idea to commercialization.
To develop a formulation that accommodate drug product manufacture to improve drug bioavailability from 60ng/ml to 80+ng/ml.
Solution:
The flow optimize is the first priority, we need to ensure the uniformity of the content of the active substance. Second, we need to improve efficiency during the packaging of the pre-existing product.
Related research will be conducted on the formulation development (optimization of excipients ratio, evaluation of active substances from different batch) and on the process parameters (blending speed, time and flow-ability). It is possible to obtain the blending parameters by the industrial reference process. The qualitative/quantitative analysis data is obtained through NIR profile and UPLC analysis. NIR profile can be used to study the correlation of powder flow-ability and type of active substances. The parameter correlations can be used in the next industrial scale up stage. Using a mathematical approach and the in-line control to determine blending uniformity, flow-ability, repose angle and density. The statistical evaluation is used to analysis and then conduct the optimization process. The blend's flow-ability is usually depended on the particle size of the active substance. Moreover, active substances from different suppliers have different physical properties that will also influence the blending process.
To develop a fixed-dose combination (FDC) drugs that was safe, effective and stable for treatment of the specific treatment regimen.
Solutions:
Preliminary clinical studies. It has been accepted that most drugs should be formulated as single compounds. There is an example of a FDC HIV drug: ATRIPLA® is an antiviral medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), which is a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. FDC drugs can help improve adherence by reducing the pills taken each day.
Drug Discovery
Drug Formulation
Drug Testing
Drug Delivery
